From 5cd10d865a10d4fae47b15d0149ec9bbb3915158 Mon Sep 17 00:00:00 2001 From: pjorbaidec Date: Tue, 8 Oct 2024 12:51:12 +0200 Subject: [PATCH] Update notebook.md --- docs/documentation/notebook.md | 56 ++++++++++++++++++++++++++++++++++ 1 file changed, 56 insertions(+) diff --git a/docs/documentation/notebook.md b/docs/documentation/notebook.md index 1075712..9a80215 100644 --- a/docs/documentation/notebook.md +++ b/docs/documentation/notebook.md @@ -1,2 +1,58 @@ # Lab notebooks +## May ++ Lab introduction ++ Cloning first level 0 (pES0001-pES0022) and level 1 constructs (pES1001-pES1027) ++ Cloning of the SP plasmids coding for SIAH1 and SIAH2 ++ Set up the first PACE reactor to evolve base editor TadA, based on a previous work by Richter _et al._[^1] + +## June ++ Cloning most level 1 (pES1028-pES1070) and first level 2 constructs (pES2001-pES2011) ++ Production of phages bearing different SP plasmids coding for SIAH1 and SIAH2 ++ Troubleshooting of the PACE reactor setup and code + +## July ++ Cloning of level 1 (pES1067-pES1103), and level 2 constructs (pES2012-pES2022), among which: + + Side-directed mutagenesis of EGLN3 to disrupt the degron motif ++ Co-transformation of pES1076+pES2008 (containing EGLN3 as a substrate) into S2060 cells ++ First propagation assay comparing SIAH1-SP, SIAH2-SP, and UN-SP ++ Set up PACE for evolution of SIAH1 using S2060 cells co-transformed with pES1076+PES2008 ++ Troubleshooting of the PACE reactor setup and code + +## August ++Cloning of level 1 (pES1104-pES1111) and level 2 (pES2023-pES2037) constructs, among which: + + Level 2 constructs with degron-mutated EGLN3 variants + + Level 2 construct without N-term RNAP ++ While SIAH1-SP phages do not wash out from the PACE lagoon, subsequent phage propagation assays show non-specific propagation ability, so the evolution is put on hold ++ Co-transformation of pES1035+pES2009 (containing α-Synuclein as a substrate) and pES1033+pES2009 (containing EGLN3 as a substrate) into S2060 cells ++ Co-transformation of degron-mutated EGLN3 variants (pES1076, pES1097, pES1098, pES1101, pES1102) with pES2008 into S2060 cells ++ Phage propagation assay with EGLN3 and α-Synuclein as substrates ++ Phage propagation assay with degron-mutated EGLN3 variants ++ Phage propagation assay for different sizes of the SP ++ Set up PACE for drift of SIAH1-SP using S2060-DP6 strain ++ As the PACE reactor needs further troubleshooting, paralelly set up PANCE for drift of SIAH1-SP using S2060-DP6 strain + +## September ++ Cloning of level 0 (pES0023-pES0028), level 1 (pES1112-pES1158) and level 2 (pES2038-pES2074) constructs, among which: + + Constructs with NLRP3 as a substrate + + Constructs with different promoter potencies controlling expression of E1 and E2 + + Constructs containing the pVan + VanR inducible system controlling expression of RNAP subunits + + Constructs containing the psp promoter controlling expression of RNAP subunits + + Level 2 constructs with SmR (spectinomycin resistance cassette) + + Level 2 constructs with different linkers for the N-term RNAP subunit - Ubiquitin fusion ++ Troubleshooting of cloning system using both Golden Gate and Gibson assembly protocols, including: + + Adaptation of the termocycler protocol for Golden Gate assembly + + Changing the resistance cassette for level 2 constructions to SmR ++ Production of a knockout SIAH1 SP plasmid (SIAH1-KO) to validate our system ++ Co-transformation of pES1076+pES2037 (no N-term RNAP system) and transformation of pES2008 only (no C-term RNAP system) in S2060 cells ++ Phage propagation assay in cells without either the N-term or the C-term RNAP subunit ++ Phage propagation assay for vanillic acid-inducible system validation ++ Assay to confirm that vanillic acid and other components of the system (e.g., RNAP subunits) are not toxic for cell growth + +## October ++ PANCE for different S2060 co-transformant strains using SIAH1-SP + + + +## References +[^1]: Richter, M.F., Zhao, K.T., Eton, E. _et al._ Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. _Nat Biotechnol_ **38**, 883–891 (2020). https://doi.org/10.1038/s41587-020-0453-z